English
Back
Open Account
牛牛名人追蹤
wrote a column · Jan 13 14:56 ·

Tracking Cathie Wood: Significantly increased positions in WGS and NTLA, reduced stake in Illumina

On Monday Eastern Time, the three major U.S. stock indexes collectively closed slightly higher, with both the S&P 500 and the Dow Jones Industrial Average hitting new all-time highs. Bolstered by strong performances in tech stocks and retail giant Walmart’s shares, investors largely shrugged off concerns stemming from the U.S. Department of Justice's criminal investigation into Federal Reserve Chair Jerome Powell.
Against this backdrop, 'Wood姐' continues to focus on her core territory—genomics and life sciences.
On Monday Eastern Time, the three major U.S. stock indexes collectively closed slightly higher, with both the S&P 500 and Dow Jones indices hitting new all-time highs. Bolstered by strong performances in tech stocks and retail giant Walmart's share price, investors largely shrugged off concerns triggered by the U.S. Department of Justice launching a criminal investigation into Fed Chair Jerome Powell. Against this backdrop, Cathie Wood remains deeply engaged in her core territory—genomics and life sciences. Key observations: Doubling down on gene therapy while selectively taking profits 1. Aggressive increase in holdings: Betting on precision medicine and gene editing Cathie Wood demonstrated strong confidence in specific biotech companies during this trading day: $GeneDx Holdings (WGS.US)$ : This was the largest increase in holdings, purchasing 133,200 shares. GeneDx focuses on genomic analysis, reflecting Cathie Wood’s optimism about the ‘data-driven diagnostics’ niche. $Intellia Therapeutics (NTLA.US)$ : Added 99,300 shares. As a leader in the gene-editing field, the increase in NTLA represents ARK’s continued bet on the commercialization prospects of CRISPR technology. $10x Genomics (TXG.US)$ and $Personalis (PSNL.US)$ Increased stakes by 50,000 shares and 17,700 shares respectively, further expanding their presence in single-cell analysis and cancer genomics sequencing...
Key Observation: Doubling down on gene therapy while selectively taking profits
1. Active Accumulation: Betting on Precision Medicine and Gene Editing
'Wood姐' displayed strong confidence in certain biotech companies during this trading session:
$GeneDx Holdings (WGS.US)$ : This was the largest increase, purchasing 133,200 shares. GeneDx focuses on genomic analysis, showing 'Wood姐's optimism about the 'data-driven diagnostics' niche.
$Intellia Therapeutics (NTLA.US)$ : Added 99,300 shares. As a leader in the gene-editing field, NTLA’s increase represents ARK’s continued bet on the commercialization prospects of CRISPR technology.
$10x Genomics (TXG.US)$ and $Personalis (PSNL.US)$ Increased holdings by 50,000 and 17,700 shares respectively, further expanding its footprint in single-cell analysis and cancer genomic sequencing.
2. Selling Actions: Structural adjustments and profit-taking
Several well-known companies appeared on the sell list:
$Illumina (ILMN.US)$ : Reduced holdings by 91,300 shares. Although Illumina is the dominant player in the sequencing industry, recent regulatory pressures or growth bottlenecks may have influenced 'Wood姐' (Cathie Wood) to make significant portfolio adjustments.
$Beam Therapeutics (BEAM.US)$ : Reduced holdings by 33,000 shares. Given that she simultaneously increased her position in NTLA, this could represent a 'picking the best among the best' strategy within the same sector or portfolio balancing.
$Teradyne (TER.US)$ : Reduced holdings by 23,000 shares. Teradyne, a semiconductor testing equipment giant, might indicate 'Wood姐' taking profits on tech hardware and reallocating funds into the biopharma sectors where she sees greater potential.
$Natera (NTRA.US)$ and $Ionis Pharmaceuticals (IONS.US)$ : Smaller-scale reductions occurred, which are part of normal portfolio management practices.
Futubull's [Opportunities Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity portfolios, follow the masters' strategies with one click, precisely lock onto high-quality targets, and invest with greater confidence!
On Monday Eastern Time, the three major U.S. stock indexes collectively closed slightly higher, with both the S&P 500 and Dow Jones indices hitting new all-time highs. Bolstered by strong performances in tech stocks and retail giant Walmart's share price, investors largely shrugged off concerns triggered by the U.S. Department of Justice launching a criminal investigation into Fed Chair Jerome Powell. Against this backdrop, Cathie Wood remains deeply engaged in her core territory—genomics and life sciences. Key observations: Doubling down on gene therapy while selectively taking profits 1. Aggressive increase in holdings: Betting on precision medicine and gene editing Cathie Wood demonstrated strong confidence in specific biotech companies during this trading day: $GeneDx Holdings (WGS.US)$ : This was the largest increase in holdings, purchasing 133,200 shares. GeneDx focuses on genomic analysis, reflecting Cathie Wood’s optimism about the ‘data-driven diagnostics’ niche. $Intellia Therapeutics (NTLA.US)$ : Added 99,300 shares. As a leader in the gene-editing field, the increase in NTLA represents ARK’s continued bet on the commercialization prospects of CRISPR technology. $10x Genomics (TXG.US)$ and $Personalis (PSNL.US)$ Increased stakes by 50,000 shares and 17,700 shares respectively, further expanding their presence in single-cell analysis and cancer genomics sequencing...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
15
Lol
1
253K Views
Report
Comment (1)
Write a Comment...
1
16
15